Immune system cancer

This Phase III trial is testing whether a single infusion of AZD0120, a CAR-T therapy that targets two proteins on myeloma cells, can keep the cancer at bay better than continuous standard treatment. It enrolls adults newly diagnosed with multiple myeloma who are not eligible for…

This trial tests a new type of cell therapy called KCAT19 for people aged 16 to 65 with advanced B-cell blood cancers that have relapsed or not responded to at least two prior treatments. The therapy uses immune cells from a donor's cord blood, which are modified to recognize and…

This phase 2 trial tests whether adjusting chemotherapy and using stem cell transplants based on each infant's genetic profile can improve survival. Infants under one year old with newly diagnosed leukemia receive a risk-stratified treatment plan. The study aims to see if this pe…

This study tests a new approach to prevent leukemia from coming back after a stem cell transplant. It uses donor T cells that have been engineered to recognize and attack a specific target (HA-2) on leukemia cells. The trial enrolls adults with acute myeloid leukemia (AML) or mye…

This trial is testing whether adding bortezomib to standard chemotherapy (CPX-351) can improve outcomes for people with a newly diagnosed, aggressive form of acute myeloid leukemia that has a TP53 mutation. The study aims to find a safe dose and see if the combination leads to mo…

This early-phase trial tests a new approach called PICX Injection, a CAR-T cell therapy that is prepared inside the patient's body rather than in a lab. It is for people with multiple myeloma that has returned or not responded to at least two prior treatments. The study will eval…

This phase 2 trial is testing whether adding the drug pacritinib to standard treatments (azacitidine or decitabine) can help more people with advanced myeloproliferative neoplasms (MPN) get a stem cell transplant. The study will enroll 27 adults whose MPN has progressed to a more…

This phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This phase 2 trial tests whether giving daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide can work as well as the standard schedule for multiple myeloma patients after a stem cell transplant. The goal is to reduce costs and clinic visits while ma…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to…

This study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see w…

This trial is testing whether adding a targeted drug called orelabrutinib to standard chemotherapy can improve outcomes for people newly diagnosed with primary central nervous system lymphoma, a rare type of brain cancer. About 215 participants will be randomly assigned to one of…

This trial is investigating whether spatially fractionated radiotherapy, a technique that delivers radiation in a grid-like pattern, can safely and effectively treat bulky (larger than 4 cm) or refractory solid tumors. The study will measure how many patients complete the treatme…

This early-phase study tests two drugs—ulixertinib and palbociclib—together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find a safe dose and check for side effects. About 45 adults whose cancers have not responded t…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This phase 3 trial is testing whether adding an experimental drug called inobrodib to a standard two-drug regimen (pomalidomide and dexamethasone) can help people whose multiple myeloma has come back or stopped responding to prior treatments. Participants will be randomly assigne…

This phase II trial is testing whether adding the drug venetoclax to standard chemotherapy can improve remission rates in younger patients with intermediate-risk acute myeloid leukemia (AML). About 153 participants will receive either standard chemo or a combination with venetocl…

This phase II trial tests whether adding gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or frail adults with a specific type of acute myeloid leukemia (FLT3-mutated) achieve deeper remission. About 147 participants will be randomly assigned…

This study tests a daily pill called olutasidenib given after a stem cell transplant to people with certain blood cancers (like AML or MDS) that have an IDH1 mutation. The goal is to see if the drug is safe and tolerable as maintenance therapy. About 31 participants will take the…

This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…

This study tests a drug called olutasidenib in people with certain early blood conditions (CCUS, lower-risk MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if the drug can control the disease and is safe. About 15 participants will take the drug and be mon…

This study tests a combination of three drugs—olutasidenib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) that has a specific IDH1 gene mutation. The goal is to find a safe and effective dose for those whose cancer has returned or not responded to treatme…

This phase 2 trial tests whether adding the drug ruxolitinib to standard care can prevent graft-versus-host disease (GVHD) in older patients with myelofibrosis or MDS/MPN overlap syndromes who receive a donor stem cell transplant. About 50 participants will get ruxolitinib before…

This early-phase trial is testing whether combining two oral drugs, eltanexor and venetoclax, is safe and effective for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study will enroll 60 adult…

This phase 3 trial compares a four-drug combination (daratumumab, bortezomib, lenalidomide, and dexamethasone) against a three-drug regimen (daratumumab, lenalidomide, and dexamethasone) in 1,450 people with newly diagnosed multiple myeloma who are not candidates for early stem c…

This phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …

This study tests a new drug called nenocorilant combined with the immunotherapy nivolumab in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 50 participants w…

This study tests a new medicine called AZD0305 in people with multiple myeloma, a type of blood cancer. The trial has two phases: first, finding a safe dose, then seeing how well it works alone or with other cancer drugs. About 226 adults will take part. The goal is to control th…

This study tests whether adding daratumumab to standard lenalidomide and dexamethasone can improve survival in people with high-risk smoldering myeloma, a condition that often progresses to active cancer. About 288 participants will receive either the standard two-drug regimen or…

This study tests an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced solid tumors. About 18 adults will receive the treatment to see if it is safe and can shrink tumors. The goal is to control the disease, no…

This study tests a drug called belantamab, given alone or with other treatments, in people with multiple myeloma. The trial has three parts: first, finding a safe dose; second, testing combinations; third, comparing the best option to standard care. About 152 participants will be…

This study tests a new way to do stem cell transplants for children with blood cancers like leukemia. It uses a half-matched family donor and removes certain immune cells from the donated cells to lower risks. The goal is to see if this method is safe and helps the child's body a…

This study tests a new oral drug, QTX-2101, combined with standard ATRA therapy for adults newly diagnosed with a low-risk form of acute promyelocytic leukemia (APL). The goal is to see if the oral capsule works as well as the current intravenous treatment. About 150 participants…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

This phase 3 trial compares an experimental drug, linvoseltamab, to an existing drug, daratumumab, in 270 people with smoldering multiple myeloma at high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the disease longer. Participants wil…

This phase 3 trial is testing whether the oral targeted drug tirabrutinib works better than a standard combination of rituximab and temozolomide for people with relapsed or refractory primary central nervous system lymphoma (PCNSL). About 132 participants will be randomly assigne…

This pilot study tests whether drinking tea made from soursop leaves can reduce the number of cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) — blood cancers that have not responded to standard treatments. About 20 particip…

This phase 2 trial compares pacritinib to the standard drug hydroxyurea in 66 adults with advanced proliferative chronic myelomonocytic leukemia (CMML). The goal is to see if pacritinib improves blood cell counts, reduces spleen size, and controls symptoms better than hydroxyurea…

This early-phase study tests a new drug (ICP-248) combined with a standard medicine (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults who have not resp…

This phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…

This phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…

This early-stage trial tests an experimental oral drug called KTX-1001 in people with multiple myeloma that has returned or not responded to prior treatments. The drug works by blocking a protein that helps myeloma cells grow. The study will enroll 165 adults and will also test K…

This early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the …

This phase 3 trial is testing a new CAR-T cell therapy called arlo-cel against standard treatments for adults with multiple myeloma that has come back or stopped responding to previous therapies. About 440 participants will receive either arlo-cel or a standard regimen. The study…

This early-stage trial is testing an investigational drug called BEBT-507 in adults with polycythemia vera, a condition where the body makes too many red blood cells. The study aims to find a safe dose and see if the drug can help control blood cell levels, potentially reducing t…

This phase II trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 28 patients with multiple myeloma that has returned or not responded to treatment and has spread to soft tissues or organs. The goal is to see if this combo can shrink tumors or …

This phase 2 trial is testing whether linvoseltamab, an investigational biologic given by infusion, can turn minimal residual disease (MRD) from positive to negative in people with newly diagnosed multiple myeloma. Participants have already received initial combination therapy bu…

This study tests an experimental drug called linvoseltamab in 220 people with AL amyloidosis that has returned or not improved after prior therapy. The drug aims to reduce abnormal proteins that damage organs like the heart and kidneys. The trial first finds the safest dose, then…

This phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a …

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This phase 3 trial will compare two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or refuse a stem cell transplant. About 500 participants will receive either belantamab mafodotin or daratumumab, both combined with standard drugs (bor…

This study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…

This early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…

This study tests a new treatment called AZD0120 for people with multiple myeloma that has come back or stopped responding to at least three prior therapies. AZD0120 is a personalized cell therapy that reprograms a patient's own immune cells to attack two targets on myeloma cells …

This phase 3 trial will test whether adding the drug quizartinib to the standard two-drug combination (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 376 people aged 18 and older who cannot receive intens…

This early-phase trial is testing a new cell therapy called CD83 CAR T cells in 26 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack a protein (CD83…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This early-stage study is testing whether combining two drugs—teclistamab and mezigdomide—is safe and effective for people with multiple myeloma that has come back or stopped responding to other treatments. About 18 participants will receive the drugs in a specific sequence. The …

This early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…

This study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC200…

This early-stage study tests a new drug, PF-07994525, in about 120 adults with advanced multiple myeloma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study has two parts:…

This phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) along with filgrastim in children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment. All participants have alr…

This study tests whether adjusting cancer drug doses for people with the Duffy null blood trait can reduce treatment delays and dangerous fevers. About 90 participants with multiple myeloma or triple-negative breast cancer will receive standard chemotherapy with modified dosing g…

This early-phase trial is testing a combination of two drugs—teclistamab and iberdomide—in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab. About 26…

This phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…

This Phase 2 trial tests the drug asciminib in 50 adults newly diagnosed with chronic myeloid leukemia (CML). The goal is to see if asciminib can control the disease and to check for side effects. Participants take the drug by mouth, and researchers monitor their health closely.

This early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…

This study tests whether adding pivekimab sunirine to the standard drugs venetoclax and azacitidine helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants will be randomly assigned to receive ei…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 adults in India with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see if the combo can put the cancer into remissio…

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This trial tests whether giving patients special immune cells, called TAA-T, after a stem cell transplant can help prevent high-risk blood cancers like acute myeloid leukemia from coming back. The cells are designed to recognize three common tumor markers and attack any remaining…

This study tests a new drug called elranatamab, alone or with another drug (daratumumab), against a standard three-drug combo for people with multiple myeloma that came back or didn't respond after at least one prior treatment. About 944 participants will be randomly assigned to …

This early-stage trial tests an investigational drug called ABBV-438 in about 127 adults with multiple myeloma that has come back or stopped responding to treatment. The study has two parts: first, finding a safe dose, then testing that dose in more people. The main goal is to ch…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This trial is testing whether an experimental drug called PBSS1113, taken as a pill alongside the standard medicine azacitidine, can help people with acute myeloid leukemia (AML) or a related condition called myelodysplastic syndrome (MDS). The study includes adults who have eith…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests a new drug called elranatamab for people with multiple myeloma that has returned or stopped responding to treatment. Half of the 492 participants will get elranatamab as a weekly shot; the other half will get one of several standard drug combinations. The goal is…

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to…

This study tests whether adding belantamab mafodotin to lenalidomide after a stem cell transplant can turn residual myeloma cells undetectable in patients with newly diagnosed multiple myeloma. About 94 adults who have already had a transplant will receive the combination therapy…

This study tests a new drug called flonoltinib maleate in 60 people with polycythemia vera (a condition where the body makes too many red blood cells) who cannot take or no longer respond to standard treatments. The goal is to see if the drug safely reduces red blood cell levels …

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…

This phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see ho…

This phase 3 trial tests a new drug called flonoltinib maleate in people with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. The study compares flonoltinib to an existing drug, ruxolitinib, to see if it can reduce spleen size and improve symptoms. About 1…

This study tests whether a new drug called SCTB35, combined with standard chemotherapy, works better than the current standard treatment (rituximab plus chemo) for people whose diffuse large B-cell lymphoma has come back or stopped responding to prior therapy. About 101 adults ag…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study tests an experimental drug called flonoltinib maleate in about 64 people with a rare bone marrow cancer (myelofibrosis) that is moderate to high risk and has not responded to or stopped responding to standard JAK inhibitor therapy. Participants take a daily pill on an …

This early-stage study tests an experimental drug called EXS73565 in about 50 adults with certain blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, while also seeing if the d…

This phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a prot…

This study compares a new combination of teclistamab and pomalidomide against the standard treatment (carfilzomib, pomalidomide, and dexamethasone) for multiple myeloma that has come back after improvement. About 162 adults with relapsed or refractory myeloma will take part. The …

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This early-phase trial tests whether adding an experimental drug called SX-682 to a standard three-drug regimen is safe for people with multiple myeloma that has relapsed or become resistant. SX-682 works by freeing up immune cells to better kill cancer cells. The study will enro…

This study tests whether a targeted drug called gemtuzumab ozogamicin can clear tiny amounts of leukemia that remain after initial treatment in adults with acute myeloid leukemia (AML). The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a chem…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This study tests an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can reduce the need for blood transfusions and increase red blood cell levels. The study is in earl…

This early-phase trial is testing a new combination of two drugs—cemsidomide (a pill) and elranatamab (a shot)—in about 60 people whose multiple myeloma has come back after prior treatments. The main goal is to see if the combination is safe and to find the best dose. Researchers…

This early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This early-phase trial tests whether injecting special immune progenitor cells (HTLPs) can help the immune system recover faster after a cord blood transplant in adults with blood cancers. Ten participants will receive the injection alongside their transplant. The goal is to see …

This early-phase trial is testing a new drug called Debio 1562M in about 134 people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The study first checks safety and finds the right dose, then looks at whether the drug can shrink the can…

This study is testing an experimental drug called SHR-4298 in 200 people with advanced solid tumors that cannot be removed by surgery or cured by standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow cancer…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This early-stage trial tests a new drug called COM503, alone or with another drug zimberelimab, in 200 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is a first-in-human study, so effe…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-phase trial tests niclosamide, a drug previously used for tapeworm infections, combined with standard chemotherapy in 16 children whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find a safe dose and check for side effe…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This phase 2 trial tests a drug called sacituzumab tirumotecan (Sac-TMT) in 30 people with advanced thymic carcinoma that has worsened after platinum-based chemotherapy. Participants receive the drug every two weeks, and doctors will check how well it shrinks tumors and monitor s…

This study is watching how well asciminib works and how safe it is in adults with a type of blood cancer called chronic myeloid leukemia. It includes people who are newly diagnosed or have already tried one other treatment. The main goal is to see how many patients reach a very l…

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This trial is testing whether combining two drugs, pacritinib and azacitidine, can help people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The study includes adults who are newly diagnosed or have had limited prior treatment. The goal is to find the safest d…

This study tests whether a combination of two drugs (elranatamab and lenalidomide) can replace high-dose chemotherapy and stem cell transplant for people newly diagnosed with multiple myeloma. About 824 adults under 70 will be randomly assigned to either standard treatment or the…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This early-stage trial tests a new drug called SIM0500 in 130 adults with multiple myeloma that has returned or stopped responding to treatment. SIM0500 is a tri-specific antibody designed to help the immune system attack cancer cells. The study will first find the safest dose, t…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This phase 2 trial tests whether combining interferon-gamma (a protein that boosts the immune system) with donor immune cells can help patients whose acute myeloid leukemia or myelodysplastic syndromes have returned after a stem cell transplant. The study will enroll 45 adults an…

This study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of a…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This clinical trial is testing whether adding the drug venetoclax to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study will enroll 324 participants and aims …

This trial is testing whether a blood test that detects HPV DNA can help doctors safely reduce the amount of radiation given after surgery for HPV-positive throat cancer. After surgery, patients with undetectable HPV DNA in their blood may receive a lower dose of radiation, while…

This trial is testing whether a chemotherapy combination called HAD, given at intermediate doses, works better than the standard regimen for people with a specific genetic subtype of acute myeloid leukemia (AML) known as CEBPA double-mutated. The study enrolls adults aged 14 to 5…

This study tests a combination of two drugs, azacitidine and enasidenib, in people with a high-risk blood cancer called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to see if the drugs can stop cancer growth and improve outcomes. …

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This phase II trial at Mayo Clinic is testing whether adding dasatinib and quercetin to standard CAR-T therapy can improve outcomes for people with multiple myeloma that has returned or not responded to prior treatments. The study will enroll 44 adults who have already tried at l…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This early-stage trial tests a combination of four drugs—lenalidomide, nivolumab, rituximab, and methotrexate—in people with primary CNS lymphoma, a rare cancer of the brain or spinal cord. The goal is to find the safest dose and see if adding lenalidomide and nivolumab to standa…

This early-phase trial is testing whether adding a patient's own blood stem cells to standard CAR T-cell therapy is safe and doable for people with relapsed or refractory blood cancers like lymphoma, leukemia, and myeloma. Twenty participants will receive their own stem cells 10 …

This early-phase trial is testing a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The main goal is to find a safe dose and check for side effects. Researchers hope this drug may offer a new option f…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-phase study tests a new kind of CAR T-cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The cells are 'armored' to resist a protein (TGF-beta) that normally blocks their attack. Up to 30 adults will re…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This Phase 3 trial compares a modified version of the standard DHAP chemotherapy regimen against the original in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The modified regimen spreads out the cisplatin and cytarabine doses over several days, aiming…

This study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…

This study tests if the drug elranatamab, given before and after a stem cell transplant, can better control high-risk multiple myeloma. About 40 adults with newly diagnosed, high-risk disease will receive the drug to reduce cancer cells before transplant and then as maintenance t…

This early-phase trial tests whether a combination of two drugs (loncastuximab tesirine and rituximab) given after precise radiation to the brain is safe and effective for central nervous system lymphoma. The study enrolls 12 adults whose lymphoma has returned or who cannot recei…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study is for people with multiple myeloma that has come back or stopped responding to other treatments. The trial has two parts: first, finding the best dose of a drug called belumosudil mesylate, and second, testing that dose alone or with dexamethasone to see if it can con…

This trial is testing whether combining various chemotherapy and targeted drugs can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who are in remission but still have traces of leukemia cells. The study enrolls patients aged 14 and older with …

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This trial is testing several different drug combinations to find the best approach for people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The study compares the effectiveness and safety of these salvage therapies, aiming to improve rem…

This trial tests a new approach for people with multiple myeloma that has come back or not responded to treatment. Doctors take immune cells from donated cord blood, genetically engineer them to better recognize and attack myeloma cells, and give them back to the patient along wi…

This study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…

This Phase 3 trial tests whether giving immune globulin (IGI) regularly can prevent serious infections in adults with multiple myeloma who are receiving a bispecific antibody therapy. About 183 participants will be randomly assigned to get IGI right away for 12 months or only aft…

This study tests a new drug called sonrotoclax, alone or with other medicines, in people with a type of multiple myeloma that has come back or stopped responding to treatment. The trial includes 246 participants and aims to find the safest and most effective dose. Researchers wil…

This study tests a new combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults with newly diagnosed acute myeloid leukemia (AML). About 30 participants will receive this therapy, followed by standard chemotherapy and, for…

This phase 2 trial tests a bispecific antibody called CM336 as maintenance therapy after stem cell transplant in 20 adults with newly diagnosed multiple myeloma who still have minimal residual disease. The goal is to see if it can clear remaining cancer cells and delay relapse.

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This study tests a drug called emapalumab to see if it can safely help people whose blood cell counts stay dangerously low after CAR T-cell therapy for certain lymphomas. About 32 adults who have already received standard CAR T-cell therapy will take part. The goal is to find out…

This phase II trial is testing a combination of three drugs—zanubrutinib, rituximab, and methotrexate—given through the vein and directly into the eye, for people newly diagnosed with primary intraocular lymphoma, a rare cancer of the eye. The goal is to see if this regimen can i…

This trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…

This trial tests a personalized approach to treating advanced solid tumors. Doctors take a patient's own immune cells, train them to recognize that patient's specific cancer mutations, and inject them back under the skin. The goal is to see if these customized cells can safely tr…

This study combines a stem cell transplant with a special immune cell therapy (C-CAR088) to treat people with ultra high-risk multiple myeloma, a blood cancer that is hard to treat. The 20 participants will receive their own stem cells after high-dose chemotherapy, followed by a …

This study tests whether combining dasatinib with ropeginterferon can better control chronic myeloid leukemia in its early phase. About 40 adults newly diagnosed with CML will receive the drug pair to see if it improves disease control and reduces side effects. The goal is to man…

This Phase 3 trial is testing whether a higher dose of the chemotherapy drug cytarabine, given with standard drugs, improves survival for people with acute myeloid leukemia (AML) that has a specific genetic change called RUNX1-RUNX1T1. The study will enroll 300 adults aged 14 to …

This study tests an experimental oral medicine called CHM-029 in adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments, and that carries specific genetic changes (NPM1 mutations or KMT2A/NUP98 rearrangements). The main goals are to fin…

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…

This trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…

This phase 2 trial is testing a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard treatment. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will measure …

This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…

This early-stage trial tests a new drug, INCA035784, in 120 adults with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check safety and find the right dose. Participants must have a specific genetic mutation (CALR) and have tried other treatments bef…

This study is for adults with a certain type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares a combination of two drugs, venetoclax and azacitidine, against standard high-dose chemotherapy as a 'consolidation' step before the …

This study tests a personalized approach for people with newly diagnosed multiple myeloma who have had a stem cell transplant. After transplant, participants receive the drug elranatamab as maintenance therapy, with the dose and duration guided by a sensitive blood test (MRD test…

This study tests whether the antiviral drug remdesivir can help treat RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer treatments or autoimmune therapies. About 60 adults with confirmed RSV will receive remdesivir intravenously. The m…

This Phase 3 trial tests whether adding the drug venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) or a related high-risk condition. About 650 participants aged 18 to 75 will receive either venetoclax or a placebo alongside chemo. …

This phase 3 trial tests whether adding the drug bleximenib to standard chemotherapy helps adults with a certain genetic type of acute myeloid leukemia (AML). About 875 people will get either bleximenib or a placebo alongside chemo, then be followed for 4 years. The goal is to se…

This early-phase trial is testing a new type of immune cell therapy called FOLR1 CAR T cells for children aged 6 and under with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy involves taking a child's own immune cells, modifying them in…

This early-stage study tests an experimental drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tum…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests a new drug, INCA033989, against the best current treatments for people with a rare blood cancer called essential thrombocythemia who have a specific gene mutation (CALR). About 426 adults who have already tried at least one prior therapy will be randomly assigned…

This early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonud…

This trial is testing whether combining a short course of focused radiation with three drugs—GM-CSF, pomalidomide, and glofitamab—can effectively treat newly diagnosed primary central nervous system diffuse large B-cell lymphoma (PCNSL), a rare and aggressive cancer of the brain …

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests a new treatment called AZD0120, which uses a patient's own immune cells engineered to attack two targets (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has returned or stopped responding to prior treatments. The study compares AZD0120 t…

This early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…

This study tests whether a combination of venetoclax and azacitidine works better than standard chemotherapy to keep high-risk acute myeloid leukemia (AML) from coming back before a stem cell transplant. About 216 adults who have already achieved remission after initial treatment…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests a new drug, cemsidomide, combined with dexamethasone in people with multiple myeloma that has returned or not responded to at least three prior treatments. About 100 adults will receive the drug combo to see if it shrinks tumors and how safe it is. The goal is to…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This early-phase study tests a new experimental drug, REGN17372, combined with another drug called linvoseltamab in people with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to treatment). The main goals are to check safety, find the best…

This trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…

This trial tests rusfertide, an injected drug, in Japanese adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The goal is to see if rusfertide can keep red blood cell levels under control and reduce the need for phlebotomy (blood removal). Al…

This phase 2 trial is testing whether paxalisib (GDC-0084), an oral drug taken daily, can shrink or control tumors in people with recurrent or refractory primary central nervous system lymphoma (PCNSL) — a rare type of non-Hodgkin lymphoma that starts in the brain or spinal cord.…

This phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…

This early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor si…

This study tests a new chemotherapy drug, L-Annamycin, combined with standard cytarabine in adults with acute myeloid leukemia (AML) that has come back or not responded to first treatment. About 312 participants will receive either the new drug combo or a placebo plus cytarabine.…

This study is testing several new drug combinations for people with multiple myeloma, a type of blood cancer. The trial is open to 200 participants who have already had some treatment. The goal is to see if these combinations are safe and help control the disease. Because multipl…

This study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to see if the combination is safe and can shrink tumors b…

This Phase 3 trial tests whether elritercept can improve anemia in people with myelofibrosis who are already taking ruxolitinib. About 324 participants will receive either elritercept or a placebo for at least 9 months. The main goal is to see if the drug reduces the need for red…

This study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…

This phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…

This early-phase trial tests a personalized therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a sample of the patient's tumor, grow them into large numbers in a lab, and infuse them back into the patient. …

This study tests whether adding the drug iberdomide to a standard treatment (belantamab mafodotin plus dexamethasone) is safe and works better for multiple myeloma that has relapsed or become resistant. About 88 participants will receive either the new combo or the standard combo…

This trial is testing whether taking tirabrutinib daily can help people with primary central nervous system lymphoma (PCNSL) stay in remission longer after their initial chemotherapy has worked. Participants who have achieved complete remission will be randomly assigned to receiv…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This early-phase trial is testing whether infusing natural killer (NK) cells from a healthy donor, combined with low-dose interleukin-2 (IL-2), can safely help treat acute myeloid leukemia (AML) that has returned after a stem cell transplant. The study involves about 12 adults wi…

This early-stage trial tests a new treatment called QUAIL-100, made from a live weakened bacteria, in children and young adults with high-risk leukemia or myelodysplastic syndrome who have already had a stem cell transplant. The main goal is to check safety and side effects. Only…

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This early-stage trial is testing a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to treatment. The main goal is to check safety and find the right dose. Up to 78 parti…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers or who have had a stem cell transplant and have a viral lung infection. Participants receive either the drug or a placebo three times over six days. The goal is to see if PUL-042 can red…

This phase 3 trial is testing whether adding revumenib, a drug that blocks a protein called menin, to the usual two-drug combination (azacitidine and venetoclax) can improve outcomes for adults newly diagnosed with acute myeloid leukemia (AML) that has a specific genetic change (…

This study tests an experimental pill called nuvisertib for people with myelofibrosis, a rare bone marrow disorder. It is for patients whose disease is moderate to high risk and who have not responded well to standard treatments. The goal is to see if the drug is safe and can shr…

This study tests whether combining two drugs, teclistamab and daratumumab, can help people newly diagnosed with both multiple myeloma and light chain amyloidosis. About 30 adults will receive the treatment for up to 24 cycles. The goal is to see if the combo improves survival wit…

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or stopped responding. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see if etentamig ca…

This phase III trial is investigating whether adding an experimental drug called BCD-248 to daratumumab can improve outcomes for people with multiple myeloma that has returned or become resistant to treatment. The study will compare this new combination against the current standa…

This early-stage study tests whether adding a new drug called revumenib to two standard chemotherapy drugs is safe for children and young adults whose acute myeloid leukemia (AML) has not responded to treatment or has returned. The study involves 24 participants and aims to find …

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This phase 2 trial is testing whether adding an experimental drug called MAX-40279 to the standard combination of venetoclax and azacitidine can help treat newly diagnosed acute myeloid leukemia (AML) in people who are not healthy enough for intensive chemotherapy. The study incl…

This early-stage trial tests an experimental drug called TQB3107, taken as a tablet, in people with advanced malignant tumors. The goal is to find a safe dose and understand how the body processes the drug. TQB3107 is designed to block a specific target inside cancer cells, poten…

This early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…

This phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…

This early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…

This trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-stage trial is testing an experimental oral drug, HPB-092, in people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The drug is designed to block two proteins, FLT3 and IRAK4, that help leukemia cells grow and survive. The stud…

This trial tests an experimental drug called CM-336 in people with high-risk smoldering multiple myeloma, a condition that often leads to active cancer. The drug is a bispecific antibody designed to guide immune cells to destroy myeloma cells. Researchers want to see if it can ma…

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This phase 3 trial tests whether combining the targeted drug venetoclax with either a short course of decitabine or a modified DA regimen (daunorubicin and cytarabine) works better than the standard 3+7 DA regimen for adults newly diagnosed with acute myeloid leukemia. About 291 …

This study tests different chemotherapy doses and a drug to prevent graft-versus-host disease in adults aged 18 to 60 with newly diagnosed acute myeloid leukemia. Participants receive either idarubicin or daunorubicin during initial chemo, followed by high or intermediate doses o…

This study tests an experimental drug, HDP-101, in people with multiple myeloma or related plasma cell disorders. The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments, including stem cell transplant or are not eligible for…

This phase 2 trial tests whether a combination of two drugs—talquetamab and lenalidomide—can help prevent multiple myeloma from returning after a stem cell transplant. The study enrolls 20 adults with symptomatic multiple myeloma who have already undergone a transplant. Participa…

This phase II trial compares the anti-cancer activity of teclistamab, an immunotherapy, against the standard combination of lenalidomide and dexamethasone in people with high-risk smoldering multiple myeloma. Smoldering myeloma is a pre-cancerous condition that often progresses t…

This study looks at whether providing food assistance—like food boxes and produce vouchers—helps cancer patients who struggle with food insecurity stay on track with their treatment. Researchers will compare patients who receive six months of food support to those who get standar…

This phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the s…

This phase 1 trial tests a new drug called GTB-3650 for adults with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug is designed to connect natural killer cells—a type of immune cell—to cancer cel…

This phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…

This trial investigates a combination of two drugs—tafasitamab, an antibody given by IV, and lenalidomide, an oral medication—for people with relapsed central nervous system (CNS) lymphoma. The study includes up to 35 participants and is the first to test this antibody in CNS lym…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to r…

This phase 3 trial tests whether adding an experimental drug called SG301 to two standard medications (pomalidomide and dexamethasone) can help people with multiple myeloma that has come back or stopped responding to treatment. About 360 adults aged 18–75 with measurable disease …

This trial tests a 16-week rehabilitation program called YATAC, designed specifically for young adults aged 18–39 who have or have had cancer. The program includes physical activity, mental health support, nutrition advice, and help with education or work. Researchers want to see…

This study tests a shorter, higher-dose-per-day radiation schedule (hypofractionated radiotherapy) given after complete surgical removal of stage II or III thymic epithelial tumors. The goal is to see if this approach is safe and tolerable, while also checking how well it control…

This trial tests a two-part treatment for people with acute myeloid leukemia (AML) that has not responded to standard therapy. First, patients receive a stem cell transplant from a healthy donor, but the stem cells are gene-edited to hide from the second treatment: specially engi…

This study tests whether a closely supervised resistance training program can improve functional mobility, body composition, and strength in people who have been treated for cancer. Participants aged 20 to 89 will follow a structured exercise regimen during or after their cancer …

This study tests a new drug called JS212 in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then expanding to see if the drug can shrink tumors. Researchers will monitor side effects and measu…

This trial investigates a personalized cell therapy called CAR-T, which reprograms a patient's own immune cells to recognize and attack a protein (BCMA) on multiple myeloma cells. The study enrolls 10 adults whose cancer has returned or become resistant after at least three prior…

This study tests a program where clinical pharmacists provide personalized counseling to cancer patients taking oral anticancer drugs. The goal is to see if this support helps patients take their medication more consistently. Researchers will compare two groups of 80 patients eac…

This study tests whether adding pioglitazone (a diabetes drug) to standard tyrosine kinase inhibitors (TKIs) can help people with chronic myeloid leukemia (CML) who lost remission after stopping TKI therapy. Participants take the combination for at least six months, then stop all…

This study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host d…

This early study tests a new treatment called SUV2208A, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CLDN18.2. The trial enrolls up to 18 adults with advanced solid tumors that ha…

This phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy, with or without a stem cell transplant, can improve outcomes for people newly diagnosed with an aggressive type of non-Hodgkin lymphoma called DLBCL. The study enrolls 30 adults aged…

This early-stage trial tests an experimental cell therapy called IBR733 for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. The therapy involves giving immune cells by vein in repeated cycles. The main goals are to check safety, …

This trial investigates CRC01, a therapy made from a patient's own immune cells that are genetically modified to recognize and attack cancer cells. It is for adults with large B-cell lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to previous tr…

This study tests a combination of four drugs, called CLAG-GO, in adults whose acute myeloid leukemia (AML) has not responded to standard treatment or has come back after remission. Participants receive the drugs during a hospital stay, and if the cancer goes into remission, they …

This phase I trial is testing a new radioactive tracer called [18F]FTT, which is used with PET/CT scans to find tumor cells in people with solid tumors, including breast, ovarian, and other cancers. The study will enroll 300 participants and aims to see how well the tracer highli…

This phase 2 trial is testing whether a radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the standard FDG tracer during PET/CT scans. The study will enroll 60 adults with newly diagnosed or relapsed/refractory multiple myeloma. Each participant w…

This trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…

This study is testing a new blood test called TuFEst that uses DNA fragments and deep learning to stage breast cancer and check if it has spread to lymph nodes. Researchers will enroll 269 breast cancer patients, including those having surgery and those receiving chemotherapy bef…

This early-stage study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes healthy volunteers and people with cancer. The goal is to improve how doctors see tumors using imaging scans.

This study tests a new blood and urine test that looks for DNA markers to detect cancer early and identify where it started. Researchers at Mayo Clinic will enroll about 6,150 people, including those with and without cancer. The goal is to see if these tests can accurately find c…

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…

This study tests whether a special PET scan using a tracer called 68Ga-Pentixafor can better detect and predict the course of blood cancers like lymphoma, multiple myeloma, and leukemia. The tracer targets a protein on cancer cells, potentially offering clearer images than standa…

This trial evaluates a radioactive tracer called 68Ga-DOTA/NOTA-FAPI-04, given as a single injection before a PET/CT scan, to see if it can better identify primary tumors and metastases in people with various cancers. Researchers will measure how strongly the tracer accumulates i…

This study compares a blood test (liquid biopsy) to the standard tissue biopsy for finding genetic changes in advanced solid tumors. The goal is to see if the liquid biopsy can accurately detect the same genetic alterations as the tissue sample. If it works, patients might avoid …

This trial investigates whether a special MRI technique using hyperpolarized carbon-13 pyruvate can safely and effectively detect primary central nervous system lymphoma, a rare type of brain cancer. Participants receive an injection of the substance before an MRI scan, and resea…

This study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to …

This study tests a new imaging agent called F18 FBPA, which is designed to light up cancer cells during a PET/CT scan. The agent targets a protein often found on solid tumors, potentially making tumors easier to see. Researchers want to find the best dose and timing for the scan,…

This study looks at a new genetic test called Caris Chromoseq for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms). The test scans the entire genome to help classify the cancer and guide risk assessment. Researc…

This study looks at whether a low dose of the antifungal drug liposomal amphotericin B can prevent serious fungal infections in adults with blood cancers or who have had stem cell transplants and have a prolonged low white blood cell count (neutropenia). The trial enrolls 30 pati…

This study tests whether a tailored physical activity program can help older adults maintain thinking and memory after a stem cell transplant for blood cancers. Participants aged 60 and older will follow a progressive, light-to-moderate exercise plan with support from therapists …

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This study compares music therapy and cognitive behavioral therapy (CBT) for reducing anxiety in people who have had cancer. 368 cancer survivors with anxiety will receive seven weekly virtual sessions of either music therapy or CBT. Researchers will track anxiety levels over 26 …

This study tests a mobile app called PACT that helps people with advanced cancer talk about and plan the care they would want if they couldn't speak for themselves. The app involves patients and their loved ones in these discussions. Researchers want to see if the app is easy to …

This study is testing a program called FOCUS ON US, designed to help sexual and gender minority (LGBTQ+) cancer patients and their caregivers. The program includes five sessions covering topics like family involvement, coping skills, and symptom management. Researchers want to se…

This study looks at whether acupuncture can help young women (ages 15-40) with cancer get their periods back after chemotherapy caused them to stop. About 60 participants will receive acupuncture or usual care. Researchers will measure how many people join and finish the study, a…

This study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …

This study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …

This study tests whether adding electroacupuncture and ear acupoint pressing beans to a standard opioid painkiller can better relieve severe cancer pain that doesn't respond to usual treatments. About 30 adults with refractory cancer pain will receive the combination for two week…

This study tests whether a 3-month personalized exercise program can improve quality of life, fitness, and symptoms in people with myeloproliferative neoplasms (MPN), a group of rare blood cancers. About 80 participants will be randomly assigned to either start the exercise progr…

This study tests whether expressive writing—reading and writing about positive experiences—can help cancer survivors manage stress. About 414 survivors will participate from home using a computer or smartphone. The goal is to see if this simple activity can lower stress and impro…

This study tests an online music therapy program that combines mindfulness and music to help people recovering from stem cell transplants for blood cancers. Researchers want to see if it can improve quality of life, reduce pain, fatigue, anxiety, and depression, and possibly spee…

This study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…

This trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…

This study tests whether psilocybin, the active ingredient in magic mushrooms, combined with talk therapy can safely help cancer survivors with depression or anxiety. Twenty adults who have finished cancer treatment and have no brain involvement will receive a single dose of psil…

This study tests a program called enCompass Humana, which provides coaching and resources to unpaid caregivers of adults with both cancer and diabetes. The goal is to see if the program is practical and helpful for caregivers, improving their coping skills and reducing loneliness…

This trial tests whether a dedicated 'return-to-work after cancer' consultation can help people who have been treated for blood cancers like leukemia, lymphoma, or multiple myeloma get back to their jobs. The consultation, led by an occupational health specialist with possible su…

This study looks at whether giving cancer survivors free healthy food and online cooking lessons can improve their health and well-being. The program is for survivors who struggle to afford food and are treated at a safety-net hospital. Researchers will check if the program is sa…

This study tests a program called CARES that provides cancer patients with integrated screening and stepped care for symptoms like pain and depression. About 1,750 adults with cancer will be randomly assigned to CARES or standard care. The goal is to see if CARES improves quality…

This study looks at whether a culturally tailored Latin dance program can help Hispanic cancer survivors sleep better. Researchers will enroll 40 adults who have finished their main cancer treatment but still have trouble sleeping. Participants will either take dance classes or c…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

This trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…

This trial tests whether using a weighted blanket during a first cancer infusion (like chemotherapy) can lower anxiety and distress compared to a regular blanket. The idea is that the deep touch pressure from the blanket may calm the nervous system and increase feelings of well-b…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approa…

This study tests a personalized program called SPOT-ON for cancer patients suffering from severe shortness of breath. Participants will receive a combination of breathing techniques, relaxation methods, posture adjustments, and oxygen-based therapies, either starting early or aft…

This trial tests whether a specially designed website, called Mosaic, can help blood cancer patients who are about to undergo a stem cell transplant feel less distressed and have a better quality of life. Participants are randomly assigned to use either the Mosaic website or a st…

This pilot trial tests whether a mobile app version of a resilience-building program, called mPRISM, is acceptable and helpful for adolescents and young adults recently diagnosed with cancer. The app teaches coping skills like stress management, goal-setting, and reframing negati…

This trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…

This study looks at whether adding pediatric palliative care consultations can improve quality of life for children with cancer and their families while they take part in early-phase (phase 1) clinical trials. Phase 1 trials test new drugs for safety, but they can cause side effe…

This trial tests whether two types of home-based digital cognitive training can help cancer survivors who have memory, attention, or thinking problems after chemotherapy. Participants will use either a computer program (BrainHQ) or a virtual reality cognitive training for 10 week…

This trial tests whether a one-page communication aid can improve how physicians and patients with cancer discuss the diagnosis. The aid, completed before the consultation, summarizes the patient's disclosure preferences and questions. Researchers will compare outcomes like patie…

This trial tests whether a short virtual program called GOLD can reduce anxiety and boost resilience in caregivers of children recently diagnosed with cancer. About 40 caregivers will either receive the two-hour GOLD session or standard information. The study measures how many ca…

This pilot study tests a hybrid intervention that combines a digital platform (Findhelp.org) with human navigation sessions to help adolescent and young adult cancer survivors manage financial and health-related social needs. Researchers will refine the approach with input from s…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This study tests whether adding a geriatric assessment visit to the standard survivorship care plan improves quality of life and satisfaction for adults aged 65 and older who have completed chemotherapy with curative intent. Participants receive either the standard care plan alon…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study en…

This study tests whether an 8-week habit-based program can help cancer survivors reduce the time they spend sitting or lying down during the day. Participants receive weekly tips, check-in sessions, and a Fitbit to encourage more movement. The goal is to see if the program is pra…

This trial tests whether a small pump implanted in the abdomen that delivers pain medicine directly to the spinal fluid can improve quality of life for people with severe cancer pain that is not controlled by oral opioids. Participants are randomly assigned to get the pump or to …

This study tests whether a combined lifestyle program—focusing on nutrition, physical activity, sleep, stress, and sense of purpose—can improve quality of life for people with cancer. It includes cancer survivors within five years of curative treatment and those with advanced can…

This study looks at whether giving blood transfusions only when hemoglobin drops below 7 gm/dL (instead of 9 gm/dL) is safe and maintains quality of life in leukemia patients after chemotherapy or stem cell transplant. About 50 adults with certain blood cancers will be randomly a…

This study tests a fertility preservation decision aid for young cancer survivors and their parents. The goal is to see if the tool helps them better understand fertility status and future parenthood options. About 358 participants will be randomly assigned to receive either the …

This study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…

This study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This study follows people of all ages who have or may have a RUNX1 gene variant, which can cause bleeding problems and increase the risk of blood cancers. Researchers will collect medical history, blood samples, and bone marrow over many years to understand how the condition deve…

This study is trying to understand why some people who get chemotherapy for cancer later develop heart issues, while others don't. Researchers will collect blood samples from 1,000 adults who have had chemotherapy, including those who had heart problems and those who didn't. By s…

This study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like leukemia or lymphoma. The tool helps patients clarify their values and shares that information with their doctors. The goal is to see if using PRIME leads to treatment decis…

This observational study will follow 4,000 people whose acute myeloid leukemia has returned or not responded to treatment. Researchers will collect data from routine care to understand survival rates and treatment patterns over up to 4 years. No new drugs are being tested; the go…

This study is a large registry that tracks cancer patients who receive both radiotherapy and molecular therapies, such as immunotherapy. The goal is to better understand how these two treatments interact and to identify how often severe side effects occur. By collecting data from…

This study looks at a new method to measure special immune cells called iNKT cells in the blood of patients who have had a stem cell transplant. These cells may help predict serious complications like graft-versus-host disease (GvHD) and relapse. Researchers will test 75 adults w…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…

This study is creating a decision aid called TA-DA to help people with advanced cancer talk with their doctors about whether to try more treatments after several have already failed. The tool is designed to support shared decision-making. Researchers will test it with 155 patient…

This study aims to find how common the KIT D816V mutation is in people with suspected clonal mast cell disease. Researchers will collect blood samples from 450 participants and test them using two sensitive methods. The results may improve understanding and diagnosis of these rar…

This early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…

This study asks 300 adolescents and young adults (ages 15-39) who have or had cancer to fill out questionnaires. The goal is to find gaps in education about exercise, sexual health, fertility, finances, and more. No treatment is given—just a survey to help improve future care.

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…

This study looks at gene changes that might cause low blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas after CAR-T therapy. About one-third of patients have low blood counts lasting more than 30 days after treatment. Researchers will test blood a…

This study tests whether a virtual community health educator (vCHE) can increase referrals to cancer clinical trials among diverse populations. Researchers will enroll 2,000 cancer patients and their caregivers across Florida. Participants interact with a computer-based agent tha…

This study is looking for 2,000 people who have a close family member with a blood cancer like multiple myeloma. The goal is to find early warning signs of the disease by collecting blood samples and health information over time. Participants will not receive any treatment, but t…

This study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…

This observational study will follow 30 multiple myeloma patients receiving a standard CAR-T therapy called cilta-cel. Researchers will collect blood, bone marrow, and other samples to find biomarkers linked to rare toxicities like nerve damage, blood issues, and gut problems. Th…

This study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…

This study tracks 170 advanced cancer patients receiving anti-VEGF therapies to record side effects and see how the disease responds. Researchers hope to find patterns linking complications to treatment success. The goal is to help doctors better understand and manage these thera…

This study looks at a type of immune cell called monocytes in people with certain blood cancers (polycythemia vera, essential thrombocythemia, and myelofibrosis). Researchers will analyze blood samples from 70 newly diagnosed patients to find unique patterns in these cells. The g…

This study tests whether a routine digital screening followed by a supportive phone call can help cancer survivors get the emotional and social support they need after finishing primary treatment. Fifty adults who have completed cancer therapy will take part. The goal is to see i…

This study looks at whether tyrosine kinase inhibitors (TKIs), the standard treatment for chronic myeloid leukemia (CML), might be linked to erectile dysfunction (ED) in men. Researchers will track 350 male patients who started TKI therapy, using questionnaires and medical record…

This study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study gathers blood and leftover tissue samples from 200 people newly diagnosed with aggressive non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and T-cell lymphoma. The samples are used to develop and validate blood-based tests that could monitor can…

This study looks at whether measuring the amount of venetoclax in the blood can help doctors give the right dose to people with newly diagnosed acute myeloid leukemia (AML). Currently, everyone gets the same dose, but drug levels vary a lot between patients. The goal is to find a…

This study looks at how cancer patients view their doctor's compassion, communication, and professionalism when the doctor uses an electronic health record (EHR) during the visit. About 88 adults with cancer will watch videos or fill out questionnaires. The goal is to understand …

This study is testing whether daily voice recordings can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. About 20 participants will use their smartphones to record their…

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…

This study follows people who previously received zamtocabtagene autoleucel, a CAR-T cell therapy for certain types of lymphoma. The goal is to monitor long-term health outcomes, including any new cancers, neurological issues, or autoimmune problems. By tracking participants over…

This study is testing a new AI tool that creates patient-friendly summaries of radiology reports for people with cancer. The goal is to see if these easy-to-read summaries help patients better understand their scan results and reduce the number of questions doctors receive. About…

This study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …

This study is testing a new questionnaire called PRO-AYA, designed to measure quality of life in adolescents and young adults (ages 15-39) with cancer. Researchers want to see if the survey is reliable and accurate, including a Spanish version. 120 participants will fill out the …

This study is testing whether people in early-phase cancer trials will consistently wear a smartwatch and complete weekly symptom surveys on a phone app. Thirty participants will use the devices for 4 weeks. The goal is to see if this approach is practical and acceptable, not to …

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study follows 260 adults newly diagnosed with cancer who have no prior sleep issues. Researchers will track how insomnia develops over the first year, using questionnaires to measure sleep quality and severity. The goal is to understand what factors—like treatment type or em…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This study explores whether MRI scans can serve as biomarkers for myelofibrosis, a bone marrow disorder. Researchers will measure water diffusion and fat content in the bone marrow using MRI before, during, and after treatment. The goal is to see if these imaging parameters can d…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This observational study tracks 7,000 men and women with cancer to see how treatments like chemotherapy, radiation, and immunotherapy affect fertility. In women, researchers measure a hormone called AMH to gauge ovarian reserve; in men, they analyze sperm quality. The goal is to …

This study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…

This study follows 400 people in Norway with multiple myeloma, plasma cell leukemia, or AL amyloidosis who are receiving newer immunotherapies like teclistamab, elranatamab, or CAR-T cell therapy outside of clinical trials. Researchers will track how well these treatments control…

This research study collects tissue samples and medical information from people with cancer who are receiving radiation therapy, as well as from healthy volunteers. The goal is to create a long-term resource that scientists can use to study how cancer responds to radiation and to…

This research study collects and analyzes blood and bone marrow samples from children and young adults with leukemia, myelodysplastic syndrome, or myeloproliferative syndrome. By reading the genetic instructions in these cancer cells, scientists hope to understand why the disease…

This study follows thousands of young adults (aged 18–40) diagnosed with solid tumors to see how their treatment affects organ preservation, fertility, and long-term quality of life. Researchers will compare them with older patients to understand unique needs. The goal is to impr…

This study tests whether cancer patients undergoing radiation therapy can use a mobile app called myCircadian Clock to record everything they eat and drink (except water and medications). Twenty adults starting radiation for cancer will use the app throughout their treatment. The…

This study tests two navigation systems—3D Slicer and Siemens Monaco—to help surgeons locate and remove abnormal lymph nodes during urologic cancer surgery. The goal is to see if these image-guided tools make the procedure simpler and more precise. Twenty adults with suspected or…

This study looks at how letting cancer patients choose which genetic results they receive affects their understanding, expectations, and satisfaction. Adults with certain cancers (cholangiocarcinoma, multiple myeloma, or early-onset colon or rectal cancer) can join. Participants …

This study looks at how daily physical activity is linked to fatigue in people who have finished or are finishing cancer treatment. Participants wear a small activity monitor and report their fatigue levels. The goal is to understand whether being more active might help reduce fa…